News & Events
We keep you up to date with our latest news.
- 심유 유동진 대표, ‘세계 임상시험의 날’ 보건복지부장관 표창 수상 2026년 5월 20일 - Recognized for Outstanding Contributions to Clinical Trial Advancement and the Development of Indigenous Digital Clinical Trial Platforms in Korea Dr. Dong Jin Yoo, Chief Executive Officer of SYMYOO Co., Ltd., has been awarded the Minister of Health and Welfare Commendation in recognition of his distinguished contributions to the advancement of clinical trials in Korea. ... 심유 유동진 대표, ‘세계 임상시험의 날’ 보건복지부장관 표창 수상
- SYMYOO, ‘바이오 코리아 2026’ 참가… 독자 기술력 선보여 2026년 4월 28일 - SYMYOO participated in ‘BIO KOREA 2026’ held at COEX for three days from April 28 to 30. Marking its 21st anniversary, this year’s event was held under the theme “Innovation and Breakthrough, Towards a Better Future,” bringing together 586 companies from 55 countries for exhibitions, business partnering, and conferences. Participating for the second ... SYMYOO, ‘바이오 코리아 2026’ 참가… 독자 기술력 선보여
- 심유, 숙명여자대학교 약학연구소(RIPS)와 전략적 공동 연구 협약 체결 2025년 5월 15일 - The Research Institute of Pharmaceutical Sciences (RIPS) at Sookmyung Women’s University and Symyoo signed a Memorandum of Understanding (MoU) to strengthen research exchange and collaboration in the fields of basic and translational biomedical sciences. This partnership is designed to foster collaboration in basic and translational medical sciences by combining the strengths and resources of ... 심유, 숙명여자대학교 약학연구소(RIPS)와 전략적 공동 연구 협약 체결
- SYMYOO, ‘바이오 코리아 2025’서 뛰어난 임상연구 역량 선보인다 2025년 5월 7일 - Symyoo, a leading full-service CRO with over 15 years of experience in clinical development, is participating in Bio Korea 2025. The company brings extensive expertise conducting over 250 clinical studies across more than 30 therapeutic areas, including oncology, rare diseases, neurology, and infectious diseases. Notably, two-thirds of Symyoo’s clinical trials have been registrational studies, highlighting ... SYMYOO, ‘바이오 코리아 2025’서 뛰어난 임상연구 역량 선보인다
- 심유, 차세대 임상시험 관리 시스템(CTMS) 1단계 공식 출시 2025년 5월 2일 - SYMYOO, a full service CRO and digital healthcare technology company, has officially announced the launch of Phase 1 of its SYNeRA™️ Clinical Trial Management System (CTMS). This release marks a significant step toward streamlining clinical trial operations and ensuring high-quality data through an integrated digital solution, setting a new standard for clinical trial digitization. All-in-one, ... 심유, 차세대 임상시험 관리 시스템(CTMS) 1단계 공식 출시
- 심유, 대규모 RRCT ‘iTARGET-Elderly’ 연구 CRO로 선정 2025년 1월 2일 - SYMYOO was selected as CRO for iTARGET-Elderly Study, a large-scale registry-based randomized controlled trial (RRCT) led by the Korean Diabetes Association (KDA). This study will compare and evaluate moderate-intensity statin therapy with an individualized LDL-C target-based therapy for the primary prevention effects of cardiovascular events in elderly patients with type 2 diabetes. The large-scale study ... 심유, 대규모 RRCT ‘iTARGET-Elderly’ 연구 CRO로 선정
- 심유, 디지털 임상연구의 혁신을 이끌다 2024년 10월 7일 - SYMYOO is on track to become the most digitalized CRO by integrating advanced IT solutions into its home-grown EDC/ Clinical Trial Management System, in order to streamline patient recruitment and to boost trial efficiency. By combining proprietary digital systems with expert personnel, Symyoo has successfully launched the Man-Unmanned Teaming Clinical Trial (MUM-T CT) model, driving innovation ... 심유, 디지털 임상연구의 혁신을 이끌다
- 심유, 대한당뇨병학회(KDA) 대규모 RRCT ‘REMATCH’ 연구 지원 2024년 1월 4일 - As a National Coordination Center, SYMYOO conducts REMATCH study, which is a very large-scale Registry-based Randomized Clinical Trial (RRCT) sponsored by the Korea Diabetes Association (KDA). This REMATCH study aims to define optimal type 2 diabetes management strategies that will improve cardiovascular and renal outcomes in type 2 diabetes mellitus patient population. Over 60 clinical ... 심유, 대한당뇨병학회(KDA) 대규모 RRCT ‘REMATCH’ 연구 지원
- SYNeRA™ 플랫폼 DB 엔진 공식 출시 2023년 3월 24일 - Smart Trial Research Center (STRC) at SYMYOO launches a new database engine, developed with multi-tier system architecture, meta-data driven and hierarchically structured database design. This SYNeRAᵀᴹ DB engine is optimized considering the systemic structural characteristics that easily reflect various system requirements from simple clinical studies to large-scale, multinational, and multi-center late-stage clinical trials, while enabling ... SYNeRA™ 플랫폼 DB 엔진 공식 출시
- 도들랩, IT 플랫폼 전문 기업으로 공식 출범 2022년 11월 1일 - Symyoo established Dodlab, Inc., to create new innovations and values under the vision ‘Making the Better Place to Live with IT Technologies’. Dodlab will pioneer new areas in the many industrial sectors, including the healthcare arena, and develop into a leading IT technology company with excellence in technology and expertise in order to help ... 도들랩, IT 플랫폼 전문 기업으로 공식 출범
- 심유, 코로나19 후기 임상시험 글로벌 총괄 센터 지정 2022년 3월 14일 - Symyoo was designated as a global coordinating center to run late phase multinational clinical trials for Covid-19 medication development. The trials are conducted widely across Korea and European countries. Symyoo understands well that the trial operations should be very specific to the risk and complexity of each region/country where the trials are conducted.
- 심유, 미국 현지 법인 ‘SYMYOO America, Inc.’ 공식 설립 2021년 11월 1일 - Established Symyoo America, Inc. in order to provide global trial consulting services for the Korean pharmaceutical, biotechnology and life-science companies wishing to enter the global market.
- 심유 EDC SYNeRA™, IWRS·RBM 신규 모듈 통합 탑재 2021년 3월 5일 - Symyoo EDC system, SYNeRA™, expanded its functionalities by integrating new modules, including IWRS (Interactive Web-based Randomization System), IP Accountability (Investigational Product Tracking and Management System), and RBM (Risk-Based Monitoring System). Symyoo IWRS can handle various randomization algorithms from simple permuted block randomization to very complex covariate adaptive randomization (biased coin, minimum sufficient).
- 심유, 한국 CDISC 협의체(K3C) CDISC/SDTM 산업 파트너 참여 2019년 11월 3일 - Symyoo participated in Korea CDISC Coordinating Committee (K3C) and achieved CDISC/SCDM industry partnership, which is granted to a company having comprehensive data management capability for clinical research.
- 심유, 창립 9주년… 누적 임상 150건·항암 임상 30건 달성 2018년 11월 23일 - Conducted more than 150 clinical studies, including 30 oncology trials over 9 years since its foundation in 2009. Symyoo had been coordinating and collaborating with various
- 심유, 차세대 EDC 플랫폼 ‘SYNeRA™’ 전격 공개 2016년 2월 24일 - Launched Symyoo EDC system, SYNeRA™ for clinical research data collection and management. Symyoo SMART TRIALS research center continues to develop and expand SYNeRA™ functionalities into a web-based Comprehensive Clinical Trial Management System.
- 심유, 고려대학교 안암 병원과 전략적 파트너십 체결 2015년 10월 12일 - Began research collaboration with Global Clinical Trial Center of Anam Hospital, Korea University Medical Center
- 심유, 한국 임상 CRO 협회 정회원 자격 획득 2014년 9월 15일 - Qualified for full membership in Korea Clinical Trial CRO Association.
- 심유, 차세대 임상시험 IT 시스템 연구를 위한 SMART TRIALS 센터 설립 2014년 7월 21일 - Established SMART TRIALS center to research and facilitate new IT technologies for tomorrow’s medicines. Symyoo reorganized data management and biostatistics team to offer broader data management services.
- 심유, 인제대학교 임상시험센터와 파트너십 체결 2013년 9월 1일 - Partnership contract with Clinical Trial Center of Baek University Hospital, Inje University
- 심유, 첫 글로벌 3상 임상시험 주관기관 선정 2012년 11월 12일 - Symyoo was designated as the Korea coordinating center to run a multinational phase III clinical trial, which was the first NIH/NINDS study (ATACH 2: Antihypertensive Treatment of Acute Cerebral Hemorrhage II) operated in South Korea. The sponsor audit was also conducted to evaluate trial conduct and compliance with the protocol and SOPs without finding any ... 심유, 첫 글로벌 3상 임상시험 주관기관 선정
- 심유, 첫 허가용 3상 임상시험 수행 2010년 3월 7일 - Symyoo expanded its business into a full scope CRO and began to operate a first phase III trial for premature ejaculation study.
- (주)심유 창립 2009년 11월 23일 - Dongjin Yoo, CEO & MD, founded a CRO to help K-Bio industry’s clinical development after his successful journey as a CEO and medical director of many global pharmaceuticals and bio startups.
